Abstract
Here, we review the most recent findings on the effects of SARS-CoV-2 infection on kidney diseases, including acute kidney injury, and examine the potential effects of ARBs on the outcomes of patients with COVID-19. Lastly, we discuss the clinical management of COVID-19 patients with existing chronic renal disorders, particularly those in dialysis and with kidney transplants.
Keywords:
Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; COVID-19; Renal and cardiac side effects; SARS-CoV-2; Severe acute respiratory syndrome coronavirus.
© 2020 S. Karger AG, Basel.
MeSH terms
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme 2
-
Angiotensin-Converting Enzyme Inhibitors
-
Angiotensins / antagonists & inhibitors*
-
Betacoronavirus / physiology
-
COVID-19
-
Coronavirus Infections / complications*
-
Humans
-
Kidney / virology
-
Kidney Diseases / complications*
-
Kidney Diseases / drug therapy*
-
Kidney Transplantation
-
Nephrologists
-
Pandemics
-
Peptidyl-Dipeptidase A
-
Pneumonia, Viral / complications*
-
Renal Dialysis
-
SARS-CoV-2
-
Virus Replication
Substances
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Angiotensins
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2